Health Blueprint

Back to Longevity News

News summary

Blue Arbor Technologies Raises $10.5 Million Series A Led by Ottobock

Source: BioSpace - Funding • Published: 29 Oct 2026, 04:16

Summarized by Masters of Longevity from BioSpace - Funding.

Blue Arbor closed a $10.5 million Series A to advance RESTORE clinical work.

Blue Arbor Technologies Raises $10.5 Million Series A Led by Ottobock
Key Takeaways
  • Ottobock led the $10.5M Series A funding round.
  • Funds will fund feasibility and an FDA IDE pursuit.
  • RESTORE has two human implants and Breakthrough status.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?